linjc16/ctgov huggingface dataset:
Mandibular Fracture Reduction Using Bone Reduction Forceps

Study Overview
=================
Brief Summary
-----------------
Different methods have been used in reducing mandibular fractures. Bone reduction forceps provides precise reduction and stabilize mandibular fracture segments.

Detailed Description
-----------------
The aim of this study is to evaluate clinically and radiographically the effect of using bone reduction forceps in the reduction of isolated mandibular fractures. 10 patients complaining of isolated mandibular fractures in need of open reduction and internal fixation underwent reduction using bone reduction forceps. The patients followed up clinically after 1 and 2 weeks, 1, 3, and 6 months postoperatively. Radiographic evaluation will be performed by computed tomography (CT) preoperatively, and cone-beam computed tomography (CBCT) will be done after 3 and 6 months

Official Title
-----------------
Evaluation of Bone Reduction Forceps in Reducing Mandibular Fracture

Conditions
-----------------
Mandibular Fractures

Intervention / Treatment
-----------------
* Device: Bone reducion forceps


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Adult patients aged from 20 to 45 years will be included. Patients suffered from recent and uninfected. Patients with isolated mandibular fractures. Exclusion criteria Medically compromised patients that will be not fit for surgery. Edentulous patients. Non-displaced Comminuted fracture with bone loss Old fracture, more than 3 weeks

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bone reduction forceps<br> | Device: Bone reducion forceps<br>* Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in radiodensitometric measurements | cone-beam computerized tomograms (CBCT) used to analyze the mean bone density at the site of fracture | at 3rd, 6th months | 
| change in maximal mouth opening | maximal interincisal opening between maxillary and mandibular central incisors. | 1 week, 2 weeks, 1 month, 6 weeks, and 3 months | 
| change in occlusion | Any occlusal disturbance including open bite or improper tooth contact will be recorded | 1 week, 2 weeks, 1 month, 6 weeks, and 3 months | 
| change in pain level | Pain: will be measured on Visual Analogue Scale (VAS). The patients will be asked to rate their postoperative pain on a 4-point scale (0= none, 1= slight, 2= moderate, 3- severe) | 1 week, 2 weeks, 1 month, 6 weeks, and 3 months |
Measuring Time Windows in Patients With Schizophrenia and Healthy Controls

Study Overview
=================
Brief Summary
-----------------
Abnormalities in the ability to distinguish events in time may have a great impact on everyday life. The main objective of the study is to evaluate the magnitude of the temporal windows in schizophrenia, i.e. the time interval during which two events are perceived as synchronous. The investigators test the hypothesis that these temporal windows are enlarged, and check the relationship between this impairment and disorganization symptoms, in order to explore the link between this cognitive impairment and clinical symptoms. They explore also the neurobiological bases of the impairment by means of electroencephalogram (EEG) recordings. Event-related potentials (N50) will reveal whether or not the coding of the stimuli has the same temporal characteristics in patients and controls. The distribution and amplitude of oscillatory activities will be analyzed as a function of the synchronous or asynchronous response of the subject, thus allowing to explore the links between synchrony perception and neuronal synchronization phenomena.

Official Title
-----------------
Relating the 'Experienced Present' With the Mechanisms of Neuronal Function: A Comparative Study in Patients With Schizophrenia and Healthy Controls Using Psychophysical and Neurophysiological Methods

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Procedure: EEG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with schizophrenia (DSM-IV criteria) Healthy controls matched with patients on age, sex and education level Age between 18 and 50 Informed consent signed No severe somatic illness No invalidating sensory disease No drug abuse, as defined by DSM-IV criteria No general anesthesia in the past 3 months No intake of drug affecting the CNS, except for patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy volunteers<br> | Procedure: EEG<br>* One 20 minutes session<br>|
| Patients<br> | Procedure: EEG<br>* One 20 minutes session<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia, Time perception, Cortical synchronization, Electroencephalography
Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification

Study Overview
=================
Brief Summary
-----------------
-Does Honan balloon reduce intraocular pressure preoperatively?

Detailed Description
-----------------
-Does Honan balloon improve surgeon's satisfaction and patients' pain score when compared to no honan group?

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Procedure: Honan balloon application


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cataract patient,who plan to undergo phacoemulsification no previous ocular surgery Exclusion Criteria: one eye high myopia Use ASA or anticoagulants History of glaucoma or ocular hypertension uncooperative patients

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Honan balloon application|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraocular pressure reduction |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain score |  |  |
Assessment of Physical Performance With A Supplementation Containing HMB in a Sample of Old Women in Good Health

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether a supplementation containing β-Hydroxy-β-methylbutyrate is effective in the treatment of age-related muscle loss in a group of older women compared to a non interventional group

Official Title
-----------------
Role of Oral Supplementation of Proteins and β-hydroxy-β-methyl Butyrate (HMB) in a Sample of Older Women in Good Health

Conditions
-----------------
Age Related Muscle Loss

Intervention / Treatment
-----------------
* Dietary Supplement: HMB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People over 65 years, not residents in nursing home, in good health Mini Mental State Examination (corrected for scholarity) more than 23 Exclusion Criteria: Previous oral supplementation with proteins or minerals important co-mordidities, such renal or hepatic failure

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Experimental: HMB<br>Group taking oral supplementation with Beta-hydroxy-beta-methylbutyrate | Dietary Supplement: HMB<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Short Physical Performance Battery |  | Baseline and after 2 months |
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

Study Overview
=================
Brief Summary
-----------------
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx)

Detailed Description
-----------------
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx) and living donor kidney transplant.

Official Title
-----------------
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

Conditions
-----------------
Renal Failure

Intervention / Treatment
-----------------
* Biological: Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient must be between the ages of 18 and 65 years and meet the institution's criteria for renal transplantation for end-organ failure Patient is receiving first renal transplant Patient is receiving a renal transplant only The crossmatch is negative between donor and recipient Women who are of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours of initiating total body irradiation (TBI) and agree to use reliable contraception for 1 year following transplant Potential donors who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving Granulocyte colony-stimulating factor (G-CSF) No evidence of donor-specific antibody presently or historically Exclusion Criteria: Clinically active bacterial, fungal, viral or parasitic infection Pregnancy Clinical or serologic evidence of viral infection which would preclude the recipient from receiving a kidney transplant Previous radiation therapy at a dose which would preclude TBI Positive crossmatch between donor and recipient Evidence for immunologic memory against donor BMI >35 or <18 Re-transplant Positive serologies for hepatitis B virus (HBV), hepatitis C virus (HCV), HIV

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kidney Transplantation
Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion

Study Overview
=================
Brief Summary
-----------------
One the day prior to medical abortion (labor induction) in the second trimester, insertion of osmotic dilators is added to the routine procedures. The study is to see whether the addition of dilators decreases the abortion time (time for the pregnancy to be expelled)

Detailed Description
-----------------
This is a pilot study and is an uncontrolled, non-randomized series. Women having a medical abortion in second trimester undergo several procedures the day before the medication to cause contractions occurs. On the day before admission, they take mifepristone orally, and have a feticidal injection. to this would be added the insertion of cervical osmotic dilators (the intervention). On the day of induction, the dilators would be removed and misoprostol started to cause contractions. We are hoping the median abortion time will drop from the present 9-10 hours to 4-6 hours. women who do not abort in 6 hours will have option of surgical completion of the abortion (dilation and evacuation) if medically appropriate.

Official Title
-----------------
Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion

Conditions
-----------------
Abortion, Induced

Intervention / Treatment
-----------------
* Device: osmotic dilator insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Requesting abortion 19-23 weeks No contraindication to induction abortion Exclusion Criteria: Fetal demise Ruptured membranes Evidence of pelvic infection Inability to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: osmotic dilator<br>osmotic dilator | Device: osmotic dilator insertion<br>* osmotic dilators are placed in the cervix to cause cervical dilation<br>* Other names: Dilapan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of Medical Abortion | This is the time elapsed from the first dose of misoprostol (the agent to induce abortion) and expulsion of the fetus | hours since the start of medical abortion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
second trimester abortion, labor induction abortion, second trimester medical abortion, pregnancy
Evaluation of Efficacy and Safety of AGP on Immune Enhancement

Study Overview
=================
Brief Summary
-----------------
The researchers investigated the immune enhancing effects of AGP for Korean participants.

Detailed Description
-----------------
The aim of the study is to investigate the effects of AGP on immune enhancement based on 8 week, randomized, double-blind, placebo-controlled clinical trial.

Official Title
-----------------
An 8 Week, Randomized, Double-blind, Placebo-controlled Clinical Trial of AGP on Immune Enhancing Effects

Conditions
-----------------
Immune Function

Intervention / Treatment
-----------------
* Dietary Supplement: AGP
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The levels of white blood cells within range 3x10^3/μL 8x10^3/μL have had at least two cold in the last 12 months. Exclusion Criteria: subjects with BMI<18.5 kg/m^2 subjects taking medications such as immune related drug or functional foods history of disease that could interfere with the test products or impede their absorption pregnant or lactating women and heavy smokers. being judged by the responsible physician of the local study center as unfit to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AGP<br>take two tablets per day (500 mg/day) for 8 weeks. | Dietary Supplement: AGP<br>* take two tablets per day (500 mg/day) for 8 weeks<br>|
| Placebo Comparator: Placebo<br>take two tablets per day for 8 weeks. | Dietary Supplement: Placebo<br>* take two tablets per day (500 mg/day) for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Natural killer cell activity | Changes of NK cell activity were assessed before and after the intervention. | 0 week, 8 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interleukin-1β | Changes of IL-1β were assessed before and after the intervention. | 0 week, 8 week | 
| Interleukin-6 | Changes of IL-6 were assessed before and after the intervention. | 0 week, 8 week | 
| Interleukin-12 (IL-12) | Changes of IL-12 were assessed before and after the intervention. | 0 week, 8 week | 
| Interferon-γ (IFN-γ) | Changes of IFN-γ were assessed before and after the intervention. | 0 week, 8 week | 
| Tumor necrosis factor-α (TNF-α) | Changes of TNF-α were assessed before and after the intervention. | 0 week, 8 week | 
| Changes of White blood cell (WBC) | Changes of WBC were assessed before and after the intervention. | 0 week, 8 week |
Measuring Corneal Cells With Specular Microscopy

Study Overview
=================
Brief Summary
-----------------
Assess changes in the corneal cell count using Specular Microscopy following tretments with Anti-VEGF injections

Detailed Description
-----------------
Patients with active Wet AMD often receive intraocular Anti-VEGF injections such as Macugen, Lucentis and Avastin on a monthly basis for an extended period of time. While these medications are very effective at controlling the Choroidal Neovascularization associated with this disease, the impact of monthly intravigtreal Anti-VEGF injections on the viability of corneal endothelial cells has yet to be fully characterized. The availability of CESM as a diagnostic test that can be performed quickly and painlessly in the clinic offers a method of tracking corneal endothelial cell count in this patient population.

Official Title
-----------------
Specular Photomicrograpic Assessment of the Effect of Anti-VEGF Intravitreal Injections on Corneal Thickness and Endothelial Cell Density and Morphology

Conditions
-----------------
Retinal Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Wet Age-related Macular Degeneration Receiving monthly intraocular injections of Anti-VEGF medication for at least 3 months Age greater than 50 years of age Exclusion Criteria: experiences adverse events

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specular Photomicrographic Assessment of the Effect of Anti-VEGF Intravitreal injections on corneal thickness and endothelial cell density and morphology | Changes in corneal endothelial cell density and corneal thickness measured by changes in pachymetry and corneal cell count. | Baseline, Month 6 and Month 12 |
Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development

Study Overview
=================
Brief Summary
-----------------
This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3 and 5 year after delivery. The purpose of this phase 1 is to : assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes; assess levels of maternal adipokines as determinants of development and fetal growth; determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns. The purpose of this phase 2 is to: identify DNA methylation variations at birth that are predictive of childhood overweight/obesity. identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity. establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age). identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3 and 5 years of age.

Official Title
-----------------
Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development

Conditions
-----------------
Gestational Diabetes, Insulin Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 yrs gestational age between 6 and 13 weeks from last menstrual period no recognized diabetes or drugs interfering with glucose metabolism alcohol < 2 drinks/day not involved in regular high intensity physical activity otherwise good health status Exclusion Criteria: twin pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Phase 1: Pregnant women<br> | |
| Phase 2: Mother-offspring dyad<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of gestational diabetes mellitus | 75g oral glucose tolerance test | 24-28 weeks of gestation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gestational diabetes, Adiponectin, Leptin, Single Nucleotides Polymorphisms, Insulin resistance